Mar 27, 2024 8:30 am EDT NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
Mar 21, 2024 8:30 am EDT LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
Feb 27, 2024 8:30 am EST Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
Feb 26, 2024 8:30 am EST LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Jan 29, 2024 8:30 am EST First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
Nov 13, 2023 8:30 am EST LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
Oct 16, 2023 8:30 am EDT LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration
Oct 9, 2023 8:30 am EDT LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
Sep 20, 2023 8:30 am EDT LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
